Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shandong Xiwang Group is a prominent Chinese industrial conglomerate with a significant presence in the life sciences sector through its specialized pharmaceutical division. The company is recognized as one of the world's largest producers of pharmaceutical-grade corn-based products, including anhydrous glucose, dextrose monohydrate, and crystalline fructose. These products are essential excipients and active ingredients used in the manufacture of intravenous fluids, oral medications, and clinical nutritional supplements. Beyond its pharmaceutical arm, the group operates extensively in the food processing and special steel industries, leveraging integrated manufacturing chains. With multiple GMP-certified facilities, Xiwang Group serves as a critical supplier to global healthcare and biotechnology companies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shandong Xiwang Group.